PMID- 27260478
OWN - NLM
STAT- MEDLINE
DCOM- 20170621
LR  - 20220316
IS  - 1867-108X (Electronic)
IS  - 1867-1071 (Linking)
VI  - 34
IP  - 8
DP  - 2016 Aug
TI  - Percutaneous radiofrequency ablation for patients with malignant lung tumors: a 
      phase II prospective multicenter study (JIVROSG-0702).
PG  - 556-63
LID - 10.1007/s11604-016-0557-z [doi]
AB  - PURPOSE: This prospective multicenter study aimed to evaluate the efficacy and 
      safety of percutaneous radiofrequency (RF) ablation for lung cancer. MATERIALS 
      AND METHODS: From May 2008 to April 2012, 33 patients (26 men, 7 women; mean age 
      70.5 years) were enrolled. RF ablation was performed using an internally cooled 
      or expandable multitined electrode. The primary endpoint was complete response 
      (CR) determined using (18)F fluorodeoxyglucose positron emission 
      tomography/computed tomography (FDG-PET/CT) performed 6 months after RF ablation. 
      The secondary endpoint was the incidence and grade of adverse events (AEs) 
      evaluated using the Common Toxicity Criteria for Adverse Events, version 3.0. 
      RESULTS: All patients underwent RF ablation and had efficacy analyses evaluated; 
      however, FDG-PET/CT images before RF ablation were not available for two 
      patients. The CR rate was 68 % (21 of 31 patients). One patient had a grade 5 AE 
      unrelated to RF ablation. Grade >/=3 AEs occurred in 12 % of patients. During the 
      follow-up period (median 37 months; range 1-55 months), five patients developed 
      local tumor progression and nine (29 %) died. Overall survival at 1, 2, and 3 
      years was 97, 82, and 74 %, respectively. CONCLUSION: Percutaneous RF ablation is 
      a safe, feasible, and effective treatment for small malignant lung tumors.
FAU - Gobara, Hideo
AU  - Gobara H
AD  - Department of Radiology, Okayama University Medical School, 2-5-1 Shikata-cho, 
      Kita-ku, Okayama City, Japan. gobara@cc.okayama-u.ac.jp.
FAU - Arai, Yasuaki
AU  - Arai Y
AD  - Department of Diagnostic Radiology, National Cancer Center, Tokyo, Japan.
FAU - Kobayashi, Takeshi
AU  - Kobayashi T
AD  - Department of Interventional Radiology, Ishikawa Prefectural Central Hospital, 
      Kanazawa, Japan.
FAU - Yamakado, Koichiro
AU  - Yamakado K
AD  - Department of Interventional Radiology, Mie University School of Medicine, Tsu, 
      Japan.
FAU - Inaba, Yoshitaka
AU  - Inaba Y
AD  - Department of Diagnostic and Interventional Radiology, Aichi Cancer Center 
      Hospital, Nagoya, Japan.
FAU - Kodama, Yoshihisa
AU  - Kodama Y
AD  - Department of Radiology, Teine Keijinkai Hospital, Sapporo, Japan.
FAU - Yamagami, Takuji
AU  - Yamagami T
AD  - Department of Radiology, Graduate School of Medical Science, Kyoto Prefectural 
      University of Medicine, Kyoto, Japan.
FAU - Sone, Miyuki
AU  - Sone M
AD  - Department of Radiology, Iwate Medical University School of Medicine, Morioka, 
      Japan.
FAU - Watanabe, Hirokazu
AU  - Watanabe H
AD  - Department of Diagnostic Radiology, National Cancer Center, Tokyo, Japan.
FAU - Okumura, Yoshihiro
AU  - Okumura Y
AD  - Department of Radiology, Fukuyama City Hospital, Fukuyama, Japan.
FAU - Shinya, Takayoshi
AU  - Shinya T
AD  - Department of Radiology, Okayama University Medical School, 2-5-1 Shikata-cho, 
      Kita-ku, Okayama City, Japan.
FAU - Kurihara, Hiroaki
AU  - Kurihara H
AD  - Department of Diagnostic Radiology, National Cancer Center, Tokyo, Japan.
FAU - Kanazawa, Susumu
AU  - Kanazawa S
AD  - Department of Radiology, Okayama University Medical School, 2-5-1 Shikata-cho, 
      Kita-ku, Okayama City, Japan.
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Multicenter Study
DEP - 20160603
PL  - Japan
TA  - Jpn J Radiol
JT  - Japanese journal of radiology
JID - 101490689
RN  - 0 (Radiopharmaceuticals)
RN  - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Non-Small-Cell Lung/diagnostic imaging/*surgery
MH  - Catheter Ablation/*methods
MH  - Female
MH  - Fluorodeoxyglucose F18
MH  - Humans
MH  - Lung/diagnostic imaging/surgery
MH  - Lung Neoplasms/diagnostic imaging/*surgery
MH  - Male
MH  - Middle Aged
MH  - Positron Emission Tomography Computed Tomography
MH  - Prospective Studies
MH  - Radiopharmaceuticals
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Clinical trial
OT  - JIVROSG
OT  - Lung cancer
OT  - Multicenter
OT  - Prospective
OT  - Radiofrequency ablation
EDAT- 2016/06/05 06:00
MHDA- 2017/06/22 06:00
CRDT- 2016/06/05 06:00
PHST- 2016/03/24 00:00 [received]
PHST- 2016/05/18 00:00 [accepted]
PHST- 2016/06/05 06:00 [entrez]
PHST- 2016/06/05 06:00 [pubmed]
PHST- 2017/06/22 06:00 [medline]
AID - 10.1007/s11604-016-0557-z [pii]
AID - 10.1007/s11604-016-0557-z [doi]
PST - ppublish
SO  - Jpn J Radiol. 2016 Aug;34(8):556-63. doi: 10.1007/s11604-016-0557-z. Epub 2016 
      Jun 3.